Abbott Laboratories $ABT Shares Sold by Narwhal Capital Management

Narwhal Capital Management cut its stake in shares of Abbott Laboratories (NYSE:ABT – Free Report) by 61.6% during the second quarter, Holdings Channel reports. The firm owned 27,594 shares of the healthcare product maker’s stock after selling 44,218 shares during the quarter. Narwhal Capital Management’s holdings in Abbott Laboratories were worth $2,504,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. MidAtlantic Capital Management Inc. acquired a new stake in Abbott Laboratories during the 4th quarter worth about $25,000. Cornerstone Financial Management LLC acquired a new position in shares of Abbott Laboratories in the fourth quarter worth about $25,000. Purpose Unlimited Inc. purchased a new position in shares of Abbott Laboratories in the fourth quarter worth approximately $25,000. Portfolio Resources Advisor Group Inc. purchased a new position in shares of Abbott Laboratories in the fourth quarter worth approximately $26,000. Finally, Abound Financial LLC acquired a new stake in shares of Abbott Laboratories during the fourth quarter valued at approximately $26,000. Institutional investors and hedge funds own 75.18% of the company’s stock.

Get Abbott Laboratories alerts:

Trending Headlines about Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott’s Instinct continuous glucose sensor is now commercially shipping in the U.S. integrated with MiniMed’s Flex automated insulin-delivery system. The partnership expands Abbott’s presence in diabetes technology and could support sensor adoption and recurring revenue. MiniMed Ships MiniMed Flex With Abbott’s Smallest Instinct Sensor
• Positive Sentiment: Abbott also entered a multiyear agreement with HealthTab to distribute its Afinion 2 point-of-care analyzers through NHS-linked pharmacies in the United Kingdom. The deal may broaden access to Abbott’s HbA1c and lipid-testing products, although financial details were not disclosed. HealthTab Enters Multi-Year Collaboration Agreement with Abbott
• Neutral Sentiment: Abbott agreed to pay approximately $670 million to resolve the Gill case and claims from roughly 2,000 individuals involving specialty formulas for premature infants. The settlement resolves a portion of the litigation, including the appeal of a prior $495 million verdict, reducing uncertainty and potentially avoiding additional legal costs. Abbott denied that its products cause necrotizing enterocolitis and said regulators and medical professionals consider the formulas safe and necessary. Abbott agrees to $670 million settlement of infant formula cases
• Negative Sentiment: The settlement represents a significant cash and earnings cost and does not resolve all potential litigation related to the infant formulas. Investors may continue to assess the scope of remaining claims and the effect on Abbott’s legal reserves and profitability. Abbott reaches agreements to resolve a portion of litigation involving its specialty formulas

Wall Street Analyst Weigh In

A number of equities analysts recently commented on ABT shares. TD Cowen reaffirmed a “buy” rating and issued a $115.00 price objective on shares of Abbott Laboratories in a research note on Friday, July 17th. Royal Bank Of Canada restated an “outperform” rating and issued a $130.00 target price on shares of Abbott Laboratories in a report on Friday, July 17th. Wells Fargo & Company raised their target price on Abbott Laboratories from $109.00 to $112.00 and gave the stock an “overweight” rating in a research report on Friday, July 17th. BTIG Research lifted their price target on Abbott Laboratories from $131.00 to $134.00 and gave the company a “buy” rating in a report on Friday, July 17th. Finally, Wolfe Research raised Abbott Laboratories from a “peer perform” rating to an “outperform” rating and set a $130.00 price target on the stock in a research report on Thursday, August 13th. Three analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $118.67.

Check Out Our Latest Stock Analysis on ABT

Abbott Laboratories Trading Up 2.2%

NYSE ABT opened at $116.62 on Friday. The company has a current ratio of 1.38, a quick ratio of 0.97 and a debt-to-equity ratio of 0.57. Abbott Laboratories has a 1-year low of $81.97 and a 1-year high of $137.49. The firm’s fifty day simple moving average is $100.08 and its 200-day simple moving average is $100.05. The company has a market capitalization of $201.80 billion, a PE ratio of 37.74, a price-to-earnings-growth ratio of 2.26 and a beta of 0.59.

Abbott Laboratories (NYSE:ABT – Get Free Report) last released its quarterly earnings data on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.28 by $0.03. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%.The firm had revenue of $12.59 billion during the quarter, compared to analysts’ expectations of $12.52 billion. During the same quarter last year, the firm earned $1.26 earnings per share. The business’s revenue for the quarter was up 13.0% on a year-over-year basis. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. As a group, sell-side analysts anticipate that Abbott Laboratories will post 5.52 earnings per share for the current fiscal year.

Abbott Laboratories Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Monday, August 17th. Investors of record on Wednesday, July 15th were given a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a yield of 2.2%. The ex-dividend date of this dividend was Wednesday, July 15th. Abbott Laboratories’s dividend payout ratio (DPR) is presently 81.55%.

Abbott Laboratories Profile

(Free Report)

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

Featured Articles

• Five stocks we like better than Abbott Laboratories
• 2 Biotech Stocks Shaping Up for Major Breakouts
• 3 Stocks Came Roaring Back—Now They’re Flashing Warning Signs
• 3 Beaten-Down Stocks That Haven’t Gotten the Message About the S&P 500’s Record Run
• Darden Restaurants Just Hit a 52-Week High–Is the Olive Garden Comeback Story Legit?

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT – Free Report).

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.